Summary
Atezolizumab has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Chronic Lymphocytic Leukaemia (CLL) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Chronic Lymphocytic Leukaemia (CLL). ClinicalTrials.gov lists 5 registered trials linking Atezolizumab to Chronic Lymphocytic Leukaemia (CLL): 1 is currently recruiting; 1 is active or not yet recruiting; 3 have completed. The most advanced is Phase 2 (NCT06043674). The largest enrolment is 713 participants (NCT02500407). Registration activity spans 2015 to 2024. No published literature item is linked to Atezolizumab and Chronic Lymphocytic Leukaemia (CLL) in the OSMF database yet, so the record rests on registry entries alone. Registry entries describe intent to study, not outcomes.
The RepurpOS disease-intelligence file for Chronic Lymphocytic Leukemia ranks 50 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Early-stage (Rai 0-I): watch-and-wait appropriate in 50-70%; spontaneous remission extremely rare; median time to treatment in Rai Stage 0: 10+ years; Richter's transformation (5-10%) extremely poor prognosis.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 36.0 (trials 16.0, literature 0.0, tier 15, approved bonus 5.0) |
| Registered trials | 5 total: 1 recruiting, 1 active / not yet recruiting, 3 completed, 0 other |
| Linked publications | 0 |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | DGIdb |
| Linked via biomarker / target | ARID1A |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT02846623 | Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome 2017 | active, not recruiting | Phase 2 | 50 |
| NCT06043674 | Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation 2024 | recruiting | Phase 2 | 70 |
| NCT02594384 | A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma 2015 | completed | Phase 1 | 62 |
| NCT02500407 | A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) 2015 | completed | PHASE1, PHASE2 | 713 |
| NCT02733042 | A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia 2016 | completed | PHASE1, PHASE2 | 106 |
Published literature
No publication is linked to this pair yet.
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target ARID1A. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Atezolizumab approved for Chronic Lymphocytic Leukaemia (CLL)?
Atezolizumab has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Chronic Lymphocytic Leukaemia (CLL) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Chronic Lymphocytic Leukaemia (CLL). Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Atezolizumab in clinical trials for Chronic Lymphocytic Leukaemia (CLL)?
ClinicalTrials.gov lists 5 registered trials linking Atezolizumab to Chronic Lymphocytic Leukaemia (CLL): 1 is currently recruiting; 1 is active or not yet recruiting; 3 have completed. The most advanced is Phase 2 (NCT06043674). The largest enrolment is 713 participants (NCT02500407). Registration activity spans 2015 to 2024.
What does the evidence show for Atezolizumab in Chronic Lymphocytic Leukaemia (CLL)?
Atezolizumab has 3 completed registered trials for Chronic Lymphocytic Leukaemia (CLL) but no linked publication, which usually means results are unpublished, pending, or not yet matched to this record. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target ARID1A. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-06. Page built 2026-10-07.